These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Williams KM; Cheng GS; Pusic I; Jagasia M; Burns L; Ho VT; Pidala J; Palmer J; Johnston L; Mayer S; Chien JW; Jacobsohn DA; Pavletic SZ; Martin PJ; Storer BE; Inamoto Y; Chai X; Flowers MED; Lee SJ Biol Blood Marrow Transplant; 2016 Apr; 22(4):710-716. PubMed ID: 26475726 [TBL] [Abstract][Full Text] [Related]
25. Epidemiology of Lower Respiratory Tract Infections and Community-Acquired Respiratory Viruses in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective Cohort Study. Epstein DJ; Liang EC; Sharifi H; Lai YK; Arai S; Graber-Naidich A; Sundaram V; Nelson J; Hsu JL Transplant Cell Ther; 2022 Oct; 28(10):705.e1-705.e10. PubMed ID: 35872303 [TBL] [Abstract][Full Text] [Related]
26. Value of Screening Spirometry for Early Diagnosis of Bronchiolitis Obliterans Syndrome in Children After Allogeneic Hematopoietic Stem Cell Transplantation. Yoon JS; Chun YH; Lee JW; Chung NG; Cho B J Pediatr Hematol Oncol; 2015 Nov; 37(8):e462-7. PubMed ID: 26334431 [TBL] [Abstract][Full Text] [Related]
27. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. Cho BS; Min CK; Kim HJ; Lee S; Kim YJ; Lim JY; Jeong DC; Cho B; Kim HK; Eom KS; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Chung NG Biol Blood Marrow Transplant; 2010 May; 16(5):629-38. PubMed ID: 19963070 [TBL] [Abstract][Full Text] [Related]
28. Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Ahn JH; Jo KW; Song JW; Shim TS; Lee SW; Lee JS; Kim DY; Lee JH; Lee JH; Choi Y; Lee KH Clin Transplant; 2015 Dec; 29(12):1133-9. PubMed ID: 26383085 [TBL] [Abstract][Full Text] [Related]
29. Risk Factor and Clinical Outcome of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Rhee CK; Ha JH; Yoon JH; Cho BS; Min WS; Yoon HK; Lee JW Yonsei Med J; 2016 Mar; 57(2):365-72. PubMed ID: 26847288 [TBL] [Abstract][Full Text] [Related]
30. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms. Kordjazy N; Amini S Ther Adv Respir Dis; 2024; 18():17534666241232284. PubMed ID: 38504551 [TBL] [Abstract][Full Text] [Related]
31. Association between chronic bacterial airway infection and prognosis of bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Yomota M; Yanagawa N; Sakai F; Yamada Y; Sekiya N; Ohashi K; Okamura T Medicine (Baltimore); 2019 Jan; 98(1):e13951. PubMed ID: 30608429 [TBL] [Abstract][Full Text] [Related]
32. Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review. Milosevic E; Babic A; Iovino L; Markovic M; Grce M; Greinix H Front Immunol; 2022; 13():1033263. PubMed ID: 36389657 [TBL] [Abstract][Full Text] [Related]
33. CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant. Sharifi H; Bertini CD; Alkhunaizi M; Hernandez M; Musa Z; Borges C; Turk I; Bashoura L; Dickey BF; Cheng GS; Yanik G; Galban CJ; Guo HH; Godoy MCB; Reinhardt JM; Hoffman EA; Castro M; Rondon G; Alousi AM; Champlin RE; Shpall EJ; Lu Y; Peterson S; Datta K; Nicolls MR; Hsu J; Sheshadri A Blood Adv; 2024 Oct; 8(19):5156-5165. PubMed ID: 39163616 [TBL] [Abstract][Full Text] [Related]
34. Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Inamoto Y; Martin PJ; Onstad LE; Cheng GS; Williams KM; Pusic I; Ho VT; Arora M; Pidala J; Flowers MED; Gooley TA; Lawler RL; Hansen JA; Lee SJ Transplant Cell Ther; 2021 Sep; 27(9):759.e1-759.e8. PubMed ID: 34126278 [TBL] [Abstract][Full Text] [Related]
35. [Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation]. Zhuang J; Gu B; Ke P; Liu YJ; Wu XJ; Xue SL; Hu XH; He XF; Ma X; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):404-410. PubMed ID: 31207706 [No Abstract] [Full Text] [Related]
36. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538 [TBL] [Abstract][Full Text] [Related]
37. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Ostrin EJ; Rider NL; Alousi AM; Irajizad E; Li L; Peng Q; Kim ST; Bashoura L; Arain MH; Noor LZ; Patel N; Mehta R; Popat UR; Hosing C; Jenq RR; Rondon G; Hanash SM; Paczesny S; Shpall EJ; Champlin RE; Dickey BF; Sheshadri A Immunohorizons; 2023 Jun; 7(6):421-430. PubMed ID: 37289498 [TBL] [Abstract][Full Text] [Related]
38. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation. Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334 [TBL] [Abstract][Full Text] [Related]
39. Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Duque-Afonso J; Ihorst G; Waterhouse M; Zeiser R; Wäsch R; Bertz H; Müller-Quernheim J; Finke J; Marks R; Prasse A Biol Blood Marrow Transplant; 2018 Nov; 24(11):2277-2284. PubMed ID: 29964193 [TBL] [Abstract][Full Text] [Related]
40. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines. Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]